R&G PharmaStudies Expands Partnership with Medidata, Deploying the Medidata Data Experience to Elevate Trial Quality and Accelerate Global Therapies

Decade-long collaboration enters a new phase as R&G evolves its use of the Medidata Platform to drive quality across multi-therapeutic full-lifecycle trials

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a strategic expansion of its enterprise partnership with R&G PharmaStudies (R&G), a leading contract research organization (CRO) in China. Through this partnership, the Medidata Data Experience will empower R&G to enhance trial data quality and compliance, enabling sponsors to accelerate the global market launch of innovative therapies. The announcement follows the milestone of R&G taking the lead in 2025 to complete the Medidata Targeted Source Data Verification (TSDV) accreditation.

By adopting the unified Medidata Data Experience—including Medidata Rave, Medidata RTSM, and Medidata Data Surveillance—R&G is further modernizing the trial lifecycle. Leveraging this technology, R&G is able to unlock the full value of clinical data, delivering improved data integrity while optimizing management capabilities with:

• Enhanced data quality: Offering robust compliance and data integrity across China’s highly competitive innovative drug landscape, including the oncology, respiratory, neurology, and endocrinology spaces.
• Management optimization: Empowering R&G to seamlessly manage multi-therapeutic full-lifecycle global trials with world-class standards.
• Accelerated global expansion: Delivering high-quality data faster to support sponsors in accelerating the market launch of new breakthrough therapies.

“Our decade-long collaboration with R&G marks a new frontier for clinical trial digitalization in China, strategically evolving our enterprise partnership. By fully integrating the Medidata Data Experience, R&G is achieving world-class standards in data integrity and trial management, acting as a powerful engine to accelerate innovative therapies onto the global stage,” said Wei (Jennifer) Li, senior vice president and general manager, Greater China, Medidata.

“Medidata is a vital strategic partner for R&G,” said Dr. Leyan Teng, co-founder, chief operating officer, and director of board at R&G. “Medidata’s global expertise and technological innovation provide robust support for our clinical trial service system and the steady growth of our business. We are delighted to solidify this strategic cooperation, capitalizing on our complementary resources to jointly build a more efficient, open, and mutually beneficial clinical trial ecosystem.”

This expansion builds upon a ten-year relationship between R&G and Medidata, established in 2015. While Medidata has supported R&G in conducting over 100 clinical trials, the move to fully integrate the Medidata Data Experience and align with shifting industry standards via TSDV accreditation marks a significant transition. By combining R&G's clinical expertise with Medidata’s Data Experience leadership, R&G is equipped to support sponsors in their global expansion with unprecedented efficiency and world-class standards.